Hubbry Logo
Mosaic (genetics)Mosaic (genetics)Main
Open search
Mosaic (genetics)
Community hub
Mosaic (genetics)
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Mosaic (genetics)
Mosaic (genetics)
Mosaic (genetics)
View on Wikipedia
from Wikipedia
Tulip flower with one side red and one side yellow.
Tulip flower showing mosaicism

Mosaicism or genetic mosaicism is a condition in which a multicellular organism possesses more than one genetic line as the result of genetic mutation.[1][2] This means that various genetic lines resulted from a single fertilized egg. Mosaicism is one of several possible causes of chimerism, wherein a single organism is composed of cells with more than one distinct genotype.

Genetic mosaicism can result from many different mechanisms including chromosome nondisjunction, anaphase lag, and endoreplication.[3] Anaphase lagging is the most common way by which mosaicism arises in the preimplantation embryo.[3] Mosaicism can also result from a mutation in one cell during development, in which case the mutation will be passed on only to its daughter cells (and will be present only in certain adult cells).[4] Somatic mosaicism is not generally inheritable as it does not generally affect germ cells.[2]

History

[edit]

In 1929, Alfred Sturtevant studied mosaicism in Drosophila, a genus of fruit fly.[5] H. J. Muller in 1930 demonstrated that mosaicism in Drosophila is always associated with chromosomal rearrangements, and Schultz in 1936 showed that, in all cases studied, these rearrangements were associated with heterochromatic inert regions. Several hypotheses on the nature of such mosaicism were proposed. One hypothesis assumed that mosaicism appears as the result of a break and loss of chromosome segments. Curt Stern in 1935 assumed that the structural changes in the chromosomes took place as a result of somatic crossing, as a result of which mutations or small chromosomal rearrangements in somatic cells. Thus the inert region causes an increase in mutation frequency or small chromosomal rearrangements in active segments adjacent to inert regions.[6]

In the 1930s, Stern demonstrated that genetic recombination, normal in meiosis, can also take place in mitosis.[7][8] When it does, it results in somatic (body) mosaics. These organisms contain two or more genetically distinct types of tissue.[9] The term somatic mosaicism was used by CW Cotterman in 1956 in his seminal paper on antigenic variation.[10]

In 1944, M. L. Belgovskii proposed that mosaicism could not account for certain mosaic expressions caused by chromosomal rearrangements involving heterochromatic inert regions. The associated weakening of biochemical activity led to what he called a genetic chimera.[non-primary source needed][6]

Types

[edit]

Germline mosaicism

[edit]
Main article: Germline mosaicism

Germline or gonadal mosaicism is a particular form of mosaicism wherein some gametes—i.e., sperm or oocytes—carry a mutation, but the rest are normal.[11][12] The cause is usually a mutation that occurred in an early stem cell that gave rise to all or part of the gametes.

Somatic mosaicism

[edit]

Somatic mosaicism (also known as clonal mosaicism) occurs when the somatic cells of the body are of more than one genotype. In the more common mosaics, different genotypes arise from a single fertilized egg cell, due to mitotic errors at first or later cleavages.

Somatic mutation leading to mosaicism is prevalent in the beginning and end stages of human life.[10] Somatic mosaics are common in embryogenesis due to retrotransposition of long interspersed nuclear element-1 (LINE-1 or L1) and Alu transposable elements.[10] In early development, DNA from undifferentiated cell types may be more susceptible to mobile element invasion due to long, unmethylated regions in the genome.[10] Further, the accumulation of DNA copy errors and damage over a lifetime lead to greater occurrences of mosaic tissues in aging humans. As longevity has increased dramatically over the last century, human genome may not have had time to adapt to cumulative effects of mutagenesis.[10] Thus, cancer research has shown that somatic mutations are increasingly present throughout a lifetime and are responsible for most leukemia, lymphomas, and solid tumors.[13]

[edit]

The most common form of mosaicism found through prenatal diagnosis involves trisomies. Although most forms of trisomy are due to problems in meiosis and affect all cells of the organism, some cases occur where the trisomy occurs in only a selection of the cells. This may be caused by a nondisjunction event in an early mitosis, resulting in a loss of a chromosome from some trisomic cells.[14] Generally, this leads to a milder phenotype than in nonmosaic patients with the same disorder.

In rare cases, intersex conditions can be caused by mosaicism where some cells in the body have XX and others XY chromosomes (46, XX/XY).[15][16] In the fruit fly Drosophila melanogaster, where a fly possessing two X chromosomes is a female and a fly possessing a single X chromosome is a sterile male, a loss of an X chromosome early in embryonic development can result in sexual mosaics, or gynandromorphs.[5][17] Likewise, a loss of the Y chromosome can result in XY/X mosaic males.[18]

An example of this is one of the milder forms of Klinefelter syndrome, called 46,XY/47,XXY mosaic wherein some of the patient's cells contain XY chromosomes, and some contain XXY chromosomes. The 46/47 annotation indicates that the XY cells have the normal number of 46 total chromosomes, and the XXY cells have a total of 47 chromosomes.

Also monosomies can present with some form of mosaicism. The only non-lethal full monosomy occurring in humans is the one causing Turner's syndrome. Around 30% of Turner's syndrome cases demonstrate mosaicism, while complete monosomy (45, X) occurs in about 50–60% of cases.

Mosaicism isn't necessarily deleterious, though. Revertant somatic mosaicism is a rare recombination event with a spontaneous correction of a mutant, pathogenic allele.[19] In revertant mosaicism, the healthy tissue formed by mitotic recombination can outcompete the original, surrounding mutant cells in tissues such as blood and epithelia that regenerate often.[19] In the skin disorder ichthyosis with confetti, normal skin spots appear early in life and increase in number and size over time.[19]

Other endogenous factors can also lead to mosaicism, including mobile elements, DNA polymerase slippage, and unbalanced chromosome segregation.[10] Exogenous factors include nicotine and UV radiation.[10] Somatic mosaics have been created in Drosophila using X‑ray treatment and the use of irradiation to induce somatic mutation has been a useful technique in the study of genetics.[20]

True mosaicism should not be mistaken for the phenomenon of X-inactivation, where all cells in an organism have the same genotype, but a different copy of the X chromosome is expressed in different cells. The latter is the case in normal (XX) female mammals, although it is not always visible from the phenotype (as it is in calico cats). However, all multicellular organisms are likely to be somatic mosaics to some extent.[21]

Gonosomal mosaicism

[edit]

Gonosomal mosaicism is a type of somatic mosaicism that occurs very early in the organisms development and thus is present within both germline and somatic cells.[1][22] Somatic mosaicism is not generally inheritable as it does not usually affect germ cells. In the instance of gonosomal mosaicism, organisms have the potential to pass the genetic alteration, including to potential offspring because the altered allele is present in both somatic and germline cells.[22]

Brain cell mosaicism

[edit]
See also: Human somatic variation § Human somatic variations in brain

A frequent type of neuronal genomic mosaicism is copy number variation. Possible sources of such variation were suggested to be incorrect repairs of DNA damage and somatic recombination.[23]

Mitotic recombination

[edit]

One basic mechanism that can produce mosaic tissue is mitotic recombination or somatic crossover. It was first discovered by Curt Stern in Drosophila in 1936. The amount of tissue that is mosaic depends on where in the tree of cell division the exchange takes place. A phenotypic character called "twin spot" seen in Drosophila is a result of mitotic recombination. However, it also depends on the allelic status of the genes undergoing recombination. Twin spot occurs only if the heterozygous genes are linked in repulsion, i.e. the trans phase. The recombination needs to occur between the centromeres of the adjacent gene. This gives an appearance of yellow patches on the wild-type background in Drosophila. another example of mitotic recombination is the Bloom's syndrome, which happens due to the mutation in the blm gene. The resulting BLM protein is defective. The defect in RecQ, a helicase, facilitates the defective unwinding of DNA during replication, thus is associated with the occurrence of this disease.[24][25]

Use in experimental biology

[edit]

Genetic mosaics are a particularly powerful tool when used in the commonly studied fruit fly, where specially selected strains frequently lose an X[17] or a Y[18] chromosome in one of the first embryonic cell divisions. These mosaics can then be used to analyze such things as courtship behavior,[17] and female sexual attraction.[26]

More recently, the use of a transgene incorporated into the Drosophila genome has made the system far more flexible. The flip recombinase (or FLP) is a gene from the commonly studied yeast Saccharomyces cerevisiae that recognizes "flip recombinase target" (FRT) sites, which are short sequences of DNA, and induces recombination between them. FRT sites have been inserted transgenically near the centromere of each chromosome arm of D. melanogaster. The FLP gene can then be induced selectively, commonly using either the heat shock promoter or the GAL4/UAS system. The resulting clones can be identified either negatively or positively.

In negatively marked clones, the fly is transheterozygous for a gene encoding a visible marker (commonly the green fluorescent protein) and an allele of a gene to be studied (both on chromosomes bearing FRT sites). After induction of FLP expression, cells that undergo recombination will have progeny homozygous for either the marker or the allele being studied. Therefore, the cells that do not carry the marker (which are dark) can be identified as carrying a mutation.

Using negatively marked clones is sometimes inconvenient, especially when generating very small patches of cells, where seeing a dark spot on a bright background is more difficult than a bright spot on a dark background. Creating positively marked clones is possible using the so-called MARCM ("mosaic analysis with a repressible cell marker" system, developed by Liqun Luo, a professor at Stanford University, and his postdoctoral student Tzumin Lee, who now leads a group at Janelia Farm Research Campus. This system builds on the GAL4/UAS system, which is used to express GFP in specific cells. However, a globally expressed GAL80 gene is used to repress the action of GAL4, preventing the expression of GFP. Instead of using GFP to mark the wild-type chromosome as above, GAL80 serves this purpose, so that when it is removed by mitotic recombination, GAL4 is allowed to function, and GFP turns on. This results in the cells of interest being marked brightly in a dark background.[27]

See also

[edit]

References

[edit]

Further reading

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Mosaic (genetics)

View on Grokipedia
from Grokipedia
In , mosaicism refers to the presence of two or more cell lineages with distinct genotypes within an individual, all derived from a single . This condition arises from post-zygotic alterations, such as mutations or chromosomal errors that occur after fertilization during embryonic development or later in life. Unlike chimerism, which involves cells from multiple zygotes, mosaicism originates from a single fertilized egg and can affect somatic (body) cells, (reproductive) cells, or both. Mosaicism is classified into two primary types based on the affected cell lines. Somatic mosaicism involves genetic differences confined to non-reproductive tissues and is not heritable, often resulting from mitotic errors during development; it may manifest as localized phenotypes like skin pigmentation changes or tumors. In contrast, affects gametes and can be transmitted to offspring, even if the parent shows no symptoms, complicating with recurrence risks estimated at 2-20% for certain de novo mutations. Mechanisms include DNA sequence variants, copy number variations (e.g., aneuploidies from or anaphase lag), and back-mutations that restore function in subsets of cells. The clinical implications of mosaicism are broad and depend on the mutation's nature, timing, and tissue distribution. It is associated with developmental disorders such as (due to mosaic PIK3CA variants), McCune-Albright syndrome (mosaic GNAS activating mutations), and mosaic forms of chromosomal conditions like or , which can be survivable only because the alterations are not uniform across all cells. Mosaicism also contributes to cancers, aging-related changes, and heritable conditions like neurofibromatosis type 1, with prevalence estimates including 0.74% nuclear mosaicism in the general population and up to 13.9% mosaic aneuploidies in IVF embryos. Diagnosis often requires targeted testing, such as next-generation sequencing of multiple tissues or prenatal methods like , to detect low-level variants that standard blood tests may miss.

Fundamentals

Definition

Genetic mosaicism refers to the presence of two or more populations of cells with distinct genotypes within a , all derived from a single . This condition arises from post-zygotic genetic changes, resulting in a mixture of cell lineages that differ genetically from the original zygotic . Unlike uniform genotypes, mosaicism introduces at the cellular level, which can persist throughout the organism's development. A key distinction exists between mosaicism and chimerism: while mosaicism originates from occurring after fertilization within a single zygotic lineage, chimerism results from the fusion or aggregation of two or more distinct zygotes, leading to multiple embryonic origins. This fundamental difference means that mosaic individuals have a unified developmental history interrupted by somatic events, whereas chimeras incorporate entirely separate genetic contributions from the outset. The implications of genetic mosaicism include the potential for heterogeneous phenotypes, where the distribution and proportion of variant cells influence the overall expression of traits or disorders. It often leads to variable expressivity in genetic conditions, with milder or atypical symptoms compared to fully constitutional mutations, depending on the timing, location, and extent of the mosaic event. For instance, low-level mosaicism may result in subtle or tissue-restricted effects, while higher levels can exacerbate phenotypic severity. Genetic mosaicism occurs across diverse multicellular organisms, including , animals, and humans, demonstrating its broad biological relevance. In , it manifests through somatic mutations in long-lived tissues, contributing to or adaptive variation. Among animals and humans, it encompasses both stable forms, where the genetic differences are fixed early in development, and dynamic forms, involving ongoing mutational accumulation over time or in response to environmental factors.

Mechanisms

Genetic mosaicism arises primarily from post-zygotic mutations, which are genetic alterations occurring in somatic cells after fertilization of the zygote. These mutations generate two or more genetically distinct cell lineages within the same individual, originating from a single zygote. The primary causes of such mutations include point mutations, which involve single nucleotide changes, and insertions/deletions (indels), which alter the length of DNA sequences. Chromosomal-level errors also contribute significantly, such as mitotic nondisjunction, where sister chromatids fail to separate properly during cell division, leading to aneuploidy in daughter cells. Another key mechanism is anaphase lagging, in which chromosomes lag behind during anaphase and are not incorporated into the nucleus, often resulting in monosomic or trisomic cell lines that may undergo corrective events like trisomy rescue. These mutations typically occur after fertilization but before or during the process of cell differentiation in embryonic development. The precise timing influences whether the affects broad somatic lineages or is restricted to specific tissues. Following the initial in a , the altered propagates through clonal expansion during , where the cell divides and passes the change to its descendants. This process creates a pattern, with clusters of genetically identical cells interspersed among normal cells, forming a patchwork distribution that varies by tissue. The extent of mosaicism, defined by the proportion of affected cells, is critically determined by the developmental timing of the . Early mutations, such as those in the first few mitotic divisions post-fertilization, can impact up to 50% of the body's cells, leading to extensive mosaicism, whereas later mutations during advanced differentiation confine the clone to a smaller fraction, often less than 1%. Conceptually, the proportion of mosaic cells pp can be approximated as p≈2−tp \approx 2^{-t}, where tt is the number of cell divisions since fertilization at the time of occurrence, under assumptions of symmetric division without selection or drift. This model highlights how an early (low tt, e.g., t=1t=1 yielding p≈0.5p \approx 0.5) results in a substantial , while a late (high tt) produces negligible mosaicism.

Historical Development

Early Discoveries

The concept of genetic mosaicism emerged from early 20th-century observations of variegated phenotypes in , where sectors of tissue displayed distinct genetic characteristics within the same individual. In the 1910s, German botanist Erwin Baur investigated green-white variegated leaves in (snapdragon), revealing that these patterns resulted from chimeric tissues composed of cells with differing genotypes, a phenomenon attributable to somatic segregation or during development. Baur's experiments demonstrated patterns in plastids, providing the first clear evidence of somatic genetic heterogeneity in . In animals, the foundational demonstration of mosaicism came from studies in . In 1936, geneticist Curt Stern reported somatic crossing over during , using the white-mottled-4 eye color mutant to show how recombination in somatic cells produced mosaic patches of pigmented and unpigmented tissue in individual flies. This work established that genetic changes could occur post-zygotically, leading to clonal lineages with altered genotypes within a single . Key insights into the mechanisms underlying mosaicism were advanced by Barbara McClintock's research on in the and 1950s. Observing mosaic color patterns in maize kernels, McClintock identified transposable elements—mobile DNA sequences that could insert or excise from genes, causing reversible mutations and sectoral variegation. Her discovery of these "controlling elements" explained how transposon activity generated somatic mosaicism, earning her the 1983 in Physiology or Medicine. In humans, mosaicism was first recognized in the context of chromosomal disorders shortly after the 1959 identification of trisomy 21 as the cause of . Initial cytogenetic analyses in the early 1960s revealed mosaic cases, such as the 1961 report by Clarke, Edwards, and Smallpeice of an intelligent child with 21-trisomy/normal mosaicism lacking typical physical features, confirmed through examination of multiple tissues showing variable counts. These findings highlighted how post-zygotic could produce mixed cell populations, milder phenotypes, and expanded the understanding of in clinical syndromes.

Key Milestones

In the cytogenetic era of the , the identification of genetic mosaicism advanced significantly through karyotyping techniques, which allowed visualization of chromosomal abnormalities in cultured cells. Pioneering work revealed mosaic forms of sex chromosome aneuploidies, such as mosaic (45,X/46,XX), where affected individuals exhibited mixed cell populations with varying complements. These discoveries, building on the establishment of human karyotyping in the late , highlighted mosaicism as a cause of variable phenotypic expression in congenital disorders, with early reports documenting mosaic trisomies in conditions like . The 1980s and 1990s marked a shift to molecular techniques that improved detection of low-level mosaicism beyond the resolution limits of traditional karyotyping. (FISH), introduced in the late , enabled targeted probing of specific chromosomal regions in cells, revealing mosaic variants at frequencies as low as 5-10% that were previously undetectable. Concurrently, (PCR) methods, including quantitative fluorescent PCR (QF-PCR) developed in the early 1990s, facilitated rapid amplification and quantification of DNA segments, proving particularly effective for identifying mosaic aneuploidies in prenatal samples. These tools expanded clinical diagnostics, such as in , where FISH on buccal cells uncovered hidden X-chromosomal mosaicism in up to 30% of cases. The 2010s introduced next-generation sequencing (NGS), revolutionizing mosaicism detection by enabling high-throughput analysis of genomic variants at single-nucleotide resolution across large cell populations. NGS surpassed earlier methods in sensitivity, identifying mosaic single-nucleotide variants (SNVs) and copy number alterations at levels below 1%, as demonstrated in studies of somatic mosaicism in neurodevelopmental disorders. Key applications included single-cell NGS protocols, which isolated and sequenced individual cells to map mosaic lineages, revealing previously unrevealed heterogeneity in embryonic and tumor tissues. For instance, targeted NGS panels quantified mosaic mutations in disease genes, detecting variants missed by Sanger sequencing. From the 2020s onward, advancements in single-cell RNA sequencing (scRNA-seq) integrated with CRISPR-based lineage tracing have elucidated the dynamic nature of mosaicism during development. These methods combine transcriptional profiling with genetic barcoding via CRISPR-Cas9 editing, allowing reconstruction of cell lineages and tracking of mosaic variant propagation in real time. In developmental models, scRNA-seq has revealed transient mosaicism in embryonic tissues, where variant frequencies fluctuate due to cell fate decisions, as seen in studies of in model organisms. CRISPR lineage tracing further demonstrated how mosaic mutations influence trajectories, providing insights into evolutionary dynamics within tissues. A pivotal milestone, the completion of the in 2003, provided a comprehensive reference sequence that facilitated the systematic identification of mosaic variants in cancer genomics. This resource enabled alignment-based detection of somatic mosaicism in tumor samples, revealing clonal expansions of mosaic mutations as drivers of oncogenesis and . Post-HGP studies using this reference highlighted increased mosaicism rates in normal tissues as a for cancer development, influencing prognostic models in ovarian and other malignancies.

Types

Germline Mosaicism

refers to the presence of a pathogenic genetic variant restricted to the germ cells ( or eggs) of an otherwise unaffected individual, resulting in the production of gametes with varying genotypes and potential transmission to multiple . This condition arises from de novo mutations occurring postzygotically in the lineage, specifically after the primordial germ cells have separated from the somatic lineage during early embryonic development. Such mutations are typically mitotic in origin, affecting a subset of germ cell precursors and leading to a mosaic population of gametes, some carrying the variant and others not. The primary consequence of germline mosaicism is its impact on inheritance patterns, where phenotypically normal parents can have more than one affected due to the transmission of the variant through mosaic gametes. This phenomenon explains apparent non-penetrance in parents and elevates the recurrence risk beyond the negligible level expected for purely de novo events; empirical estimates suggest a general risk of 1-5% for subsequent affected pregnancies, though it can reach 8-12% in conditions like depending on the extent of gonadal involvement. In pedigrees with multiple affected siblings and no parental , this mosaicism accounts for the deviation from Mendelian expectations, necessitating adjusted . Representative examples include de novo mutations in the causing , where parental has been documented in families with recurrent affected offspring despite normal parental testing. Similarly, in hemophilia A, for F8 gene variants in unaffected fathers or mothers can lead to multiple hemophiliac sons, as reported in cases where the is confined to gonadal cells. These instances highlight how germline-limited variants propagate heritable disorders without somatic manifestations in the carrier parent. Detection of germline mosaicism typically involves comparing genetic material from somatic tissues (e.g., ) with that from germ cells, such as through sequencing of sperm DNA to quantify the proportion of variant-carrying gametes. For at-risk families, (PGD) enables screening of embryos for the variant during in vitro fertilization, allowing selection of unaffected ones and mitigating recurrence risk. Advanced techniques like droplet digital PCR further refine detection by assessing low-level mosaicism in gametes.

Somatic Mosaicism

Somatic mosaicism arises from postzygotic in non-germline cells, resulting in genetically distinct cell populations within an individual's body. These occur after fertilization, during embryonic development or later in life, and can affect single , larger genomic segments, or entire chromosomes in lineages. Depending on the timing and location of the , the mosaicism may be confined to specific tissues or distributed more widely across the body, leading to a mosaic pattern of that is not heritable to offspring. The phenotypic consequences of somatic mosaicism exhibit significant variability, primarily determined by the developmental stage at which the occurs, the proportion of affected cells, and the specific tissues involved. Early postzygotic , arising soon after fertilization, can propagate to a large fraction of cells (e.g., up to 50% if occurring at the first mitotic division), often resulting in more pronounced and systemic effects. In contrast, later in development or adulthood typically involve fewer cells and may produce milder or localized phenotypes, with severity escalating if critical organs like the are impacted compared to less vital areas such as the skin. This variability underscores how somatic mosaicism can range from clinically silent to severely debilitating, influencing individual health outcomes in diverse ways. Prevalence estimates indicate that somatic mosaicism is relatively common in the population, with detectable variants present in approximately 1-2% of healthy adults, particularly in hematopoietic tissues, and increasing sharply with age due to accumulated . In aging individuals, rates can rise to 10% or higher for clonal events in blood, while in embryos, up to 70% may harbor mosaic copy number variations or aneuploidies that often resolve or remain confined. Higher prevalence is also observed in cancer-prone or disease-affected populations, highlighting its role in both normal variation and . From an evolutionary perspective, somatic mosaicism contributes to intra-individual , potentially enhancing adaptability by allowing cellular populations to respond to environmental pressures, as seen in repertoire generation through . However, this diversity comes at the cost of increased risk, including accelerated aging and oncogenesis, as mutant clones can expand and dominate tissues over time. Thus, while somatic mutations may confer short-term advantages in specific contexts, their accumulation generally promotes vulnerability to disorders. Detecting somatic mosaicism presents substantial challenges owing to its uneven distribution across tissues and the typically low frequency of mutant alleles, often below 5-10% in sampled cells. Standard methods like fail to identify variants under 15-20% , necessitating advanced techniques such as ultra-deep next-generation sequencing (requiring >500x coverage) or to achieve sensitivity for low-level events. Moreover, accurate detection demands targeted sampling from affected tissues rather than peripheral blood, as mosaicism may be absent or diluted in easily accessible samples, complicating clinical and .

Specific Manifestations

Chromosomal Mosaicism

Chromosomal mosaicism refers to the presence of two or more cell populations with distinct complements within an , specifically involving gains, losses, or structural alterations of entire arising post-zygotically. This form of mosaicism contrasts with uniform by resulting in a of euploid and aneuploid cells, often leading to variable phenotypic expression depending on the distribution and proportion of affected cells. Common types include mosaic trisomies, where an extra is present in some cells, and monosomies, characterized by the loss of a in a subset of cells. The primary mechanisms underlying chromosomal mosaicism occur during mitotic divisions after fertilization, with nondisjunction—failure of sister chromatids to separate properly—and anaphase lag—delayed migration of a chromosome leading to its exclusion from the nucleus—being the most frequent causes. typically produces trisomic and daughter cells in equal proportions, while anaphase lag more commonly results in due to the lagging forming a or being degraded. Studies indicate that anaphase lag accounts for over 50% of mosaic embryos in preimplantation development. Clinically, the severity of chromosomal mosaicism varies with the mosaic fraction, the proportion of aneuploid cells, and the tissues affected; for instance, fractions of 20-50% often yield milder phenotypes compared to full aneuploidy, as the euploid cells mitigate the imbalance. In mosaic trisomy 21, associated with Down syndrome, individuals exhibit partial expression of features such as intellectual disability and congenital heart defects, with lower trisomic cell percentages (e.g., mean 37% in lymphocytes) correlating to fewer traits. Similarly, mosaic monosomy X (45,X/46,XX) in Turner syndrome presents with reduced severity, including less frequent cardiac anomalies and better growth outcomes than non-mosaic cases. Another example is mosaic Klinefelter syndrome (47,XXY/46,XY), which comprises about 10% of Klinefelter cases and is linked to subtler hypogonadism and fertility issues; overall Klinefelter prevalence is approximately 1 in 500-1000 male births. Diagnosis of chromosomal mosaicism requires karyotyping of multiple tissues, such as , fibroblasts, or buccal smears, to accurately determine the mosaic fraction and avoid underestimation from single-site sampling. Advanced techniques like chromosomal analysis complement karyotyping for detecting low-level mosaicism, and professional guidelines, including those from the American College of Medical Genetics and Genomics (ACMG), emphasize standardized reporting of mosaic findings to guide clinical management.

Tissue-Specific Mosaicism

Tissue-specific mosaicism refers to the presence of genetically distinct cell populations confined to particular organs or cell lineages, arising from postzygotic that do not disseminate widely during embryonic development. This form of mosaicism often involves point or small genetic alterations rather than large-scale chromosomal changes, leading to localized phenotypic effects within affected tissues. Such mosaicism is particularly evident in ectodermally derived structures like the and , where divisions create clonal patches of mutant cells. In the , somatic mutations occurring in neuronal progenitors during early development can propagate to subsets of neurons, contributing to neurodevelopmental disorders such as autism spectrum disorder (ASD) and . For instance, activating mutations in PIK3CA, a in the PI3K-AKT-mTOR pathway, have been identified in brain tissue from individuals with focal epilepsy and hemimegalencephaly, correlating with seizure severity and brain overgrowth. These mutations, detected at low variant allele frequencies (e.g., 1-15%), highlight the tissue-restricted nature of the mosaicism, as they are often undetectable in peripheral blood. Similarly, in ASD, somatic variants in genes like MECP2 or those affecting regulation arise in neural progenitors, potentially altering synaptic connectivity in specific cortical regions and accounting for 3-5% of cases without findings. Skin and gonadal tissues frequently exhibit tissue-specific mosaicism due to mutations in signaling pathways that influence ectodermal and gonadal development. McCune-Albright syndrome exemplifies this, caused by mosaic activating mutations in GNAS, leading to autonomous endocrine hyperfunction and fibrous dysplasia confined to affected skeletal regions, with café-au-lait spots following Blaschko's lines in the skin. In the gonads, these mutations can manifest as precocious puberty in females through ovarian cysts or, less commonly, testicular enlargement in males, underscoring the postzygotic origin and variable tissue involvement. Gonosomal mosaicism, such as 45,X/46,XY karyotypes, results in mixed gonadal dysgenesis with asymmetric development—one streak gonad and one dysgenic testis—predominantly affecting gonadal ridges and contributing to ambiguous genitalia or infertility, while sparing other tissues like blood. Mitotic recombination serves as a key mechanism generating tissue-specific mosaicism by promoting (LOH) during cell division, particularly in proliferative tissues like tumors or developmental primordia. This process involves between chromosomes, leading to daughter cells that are homozygous for a over large genomic segments, often without copy number changes. In developmental contexts, such recombination in cells creates clonal patches, as observed in mammary tumors where LOH via mitotic recombination associates with strain-specific susceptibility, propagating clones within the tissue. The implications of tissue-specific mosaicism include the emergence of segmental phenotypes, where mutant cells form discrete patches along developmental lines, such as the linear lesions in . This X-linked disorder, driven by IKBKG mutations and , produces Blaschkolinear vesicular and hyperpigmented streaks due to clonal expansion of mutant in the , with potential extension to dental or ocular tissues but sparing unaffected areas. These localized manifestations emphasize how mosaicism can drive organ-specific pathology without systemic effects. Recent advances in single-nucleus sequencing have revealed that even healthy harbor substantial neuronal mosaicism, with studies estimating that up to 10% of excitatory neuron progenitors contribute somatic single-nucleotide variants to cortical columns, accumulating 16-17 variants per annually with age. These findings, from deep sequencing of postmortem brain samples, indicate that low-level mosaicism is a normal feature of brain development, potentially influencing individual variability in or resilience to neurological insults.

Research Applications

Experimental Models

Experimental models of genetic mosaicism utilize various organisms and techniques to investigate the effects of genetic variants in specific cell populations, enabling precise dissection of cellular and developmental processes. In , the FLP-FRT system facilitates , generating mosaic clones where cells homozygous for a are created amid a heterozygous background, allowing analysis of recessive phenotypes without lethality in the whole organism. This approach has been instrumental in mapping gene functions during development by inducing targeted . The nematode serves as a model for lineage tracing in mosaicism studies due to its invariant and transparency, which permit detailed observation of how genetic alterations propagate through embryonic divisions. Mosaic animals are generated by spontaneous loss of extrachromosomal arrays or targeted methods, revealing cell-autonomous requirements for genes in specific lineages. Similarly, the zebrafish is employed for inducible mutations, leveraging tools like the zMADM (zebrafish mosaic analysis with double markers) system to label and analyze mutant clones , particularly in neural and skeletal development. In mice, the Mosaic Analysis with Double Markers (MADM) system enables the generation of homozygous mutant cells in an otherwise heterozygous animal through interchromosomal recombination during . This technique is particularly valuable for studying somatic mosaicism in mammalian development, allowing visualization and genetic labeling of mutant clones to assess cell-autonomous effects and tissue contributions. Advanced techniques such as CRISPR- enable targeted somatic editing to produce mosaic embryos, where guide RNAs and Cas9 nucleases introduce in a subset of cells during early cleavage stages, mimicking somatic variants observed in nature. This method generates diverse allelic outcomes in individual cells, facilitating studies of spectra and repair mechanisms. Complementing this, mosaic analysis with short hairpin RNAs (MOSH) in uses RNAi to achieve tissue-specific or clonal knockdown, though persistent silencing can complicate interpretation by extending beyond target clones. These models find applications in elucidating function, where mosaic knockouts uncover functional redundancy by comparing mutant and wild-type cells within the same organism; in , they reveal clonal contributions to tissue patterning; and in evolutionary studies, they model how somatic mutations influence and . For instance, mosaic analysis in has demonstrated how inactivation in specific clones affects , highlighting compensatory mechanisms. A key advantage of these experimental models is their ability to introduce controlled genetic variants, permitting the isolation of clonal effects and cell-cell interactions without systemic perturbations. However, limitations arise from species-specific differences, such as divergent organization and developmental timing, which may reduce direct relevance to mosaicism and necessitate validation in mammalian systems.

Clinical and Diagnostic Uses

In clinical practice, detecting genetic mosaicism is crucial for accurate , particularly when variant frequencies (VAFs) are ultra-low, often below 5%. Next-generation sequencing (NGS) panels designed for mosaicism enable the identification of such low-level variants in blood or tissue samples from patients with neurodevelopmental disorders or other conditions. Droplet digital PCR (ddPCR) complements NGS by providing precise quantification of mosaic variants, achieving sensitivity for VAFs as low as 0.001% and outperforming conventional PCR in underrepresented low-frequency mutations. Combining ultra-deep NGS with ddPCR further enhances diagnostic accuracy for gonosomal or copy number variant mosaicism in challenging cases. These methods are routinely applied in to uncover somatic or contributing to idiopathic disorders. Prenatal screening for mosaicism has advanced with non-invasive prenatal testing (NIPT), which analyzes to detect confined placental mosaicism (CPM), a common cause of discrepancies between screening and fetal outcomes. NIPT-positive results for aneuploidies like trisomy 13 may indicate low-level mosaic events confined to the , prompting further evaluation. Confirmation typically requires invasive procedures such as , which provides direct fetal karyotyping or molecular analysis to distinguish true fetal mosaicism from placental-specific findings and guide pregnancy management. Therapeutic strategies for mosaic conditions leverage targeted approaches, especially in oncology where mosaic mutations drive tumor heterogeneity. In melanomas harboring mosaic BRAF V600E mutations, BRAF inhibitors like or , often combined with MEK inhibitors, offer effective control by disrupting oncogenic signaling pathways. For broader somatic mosaicism in genetic diseases, gene editing technologies such as / hold potential for correcting mosaic variants in affected cell lineages, as demonstrated in preclinical models for immunodeficiencies like . Genetic counseling plays a pivotal role in managing families affected by , where parental gonadal mosaicism elevates recurrence risks beyond the typical 1-2% for de novo variants. Assessments using ddPCR or NGS on parental gametes or somatic tissues refine these risks, with estimates ranging from 4.3% to 11% for maternal mosaicism in certain disorders, informing reproductive options like preimplantation genetic testing. As of 2025, emerging AI-assisted tools are transforming mosaicism detection in data, enabling precise variant calling for ultra-rare somatic events in workflows. Machine learning algorithms, integrated with NGS pipelines, improve sensitivity for mosaic variants in precision and developmental disorders, facilitating tailored interventions.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK559193/
  2. https://www.genome.gov/genetics-glossary/Mosaicism
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC11507335/
  4. https://www.ncbi.nlm.nih.gov/books/NBK585455/
  5. https://www.sciencedirect.com/science/article/pii/S1098360021007693
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC3146011/
  7. https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2022.802362/full
  8. http://www.nature.com/scitable/topicpage/somatic-mosaicism-and-chromosomal-disorders-867
  9. https://www.annualreviews.org/doi/pdf/10.1146/annurev.es.26.110195.002231
  10. https://nph.onlinelibrary.wiley.com/doi/10.1111/nph.17476
  11. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0198011
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC7206664/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC4490042/
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC1208727/
  15. https://doi.org/10.1016/S0140-6736(61)91833-5
  16. https://www.ncbi.nlm.nih.gov/books/NBK554621/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC4519034/
  18. https://www.sciencedirect.com/science/article/am/pii/S1383571818302237
  19. https://academic.oup.com/humupd/article/10/6/541/626971
  20. https://www.researchgate.net/publication/255734280_Buccal_cell_FISH_and_blood_PCR-Y_detect_high_rates_of_X_chromosomal_mosaicism_and_Y_chromosomal_derivatives_in_patients_with_Turner_syndrome
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC4819561/
  22. https://www.science.org/doi/10.1126/science.aal1641
  23. https://www.cell.com/molecular-cell/pdfExtended/S1097-2765%2815%2900341-X
  24. https://www.researchgate.net/publication/296686861_Detection_and_Quantification_of_Mosaic_Mutations_in_Disease_Genes_by_Next-Generation_Sequencing
  25. https://ui.adsabs.harvard.edu/abs/2020NatCo..11.3055Z/abstract
  26. https://www.biorxiv.org/content/10.1101/2024.11.15.623872v1
  27. https://pubmed.ncbi.nlm.nih.gov/39046878/
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC5942543/
  29. https://www.icr.ac.uk/about-us/icr-news/detail/how-the-human-genome-project-shook-the-world-of-cancer-research
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC4276927/
  31. https://www.aacr.org/blog/2022/08/22/genetic-mosaicism-how-mutations-that-arise-in-the-embryo-may-cause-cancer-later-in-life/
  32. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/germline-mosaicism
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC8483770/
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC3215430/
  35. https://humgenomics.biomedcentral.com/articles/10.1186/s40246-023-00535-y
  36. https://pubmed.ncbi.nlm.nih.gov/19475718/
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC9550265/
  38. https://pubmed.ncbi.nlm.nih.gov/7720740/
  39. https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2516.2009.02003.x
  40. https://www.sciencedirect.com/science/article/pii/S1071909124000366
  41. https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2022.1011833/full
  42. https://doi.org/10.1038/ng.2270
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC5480293/
  44. https://pubmed.ncbi.nlm.nih.gov/25223253/
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC8609036/
  46. https://pubmed.ncbi.nlm.nih.gov/24667481/
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC7125259/
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC3707311/
  49. https://medlineplus.gov/genetics/condition/klinefelter-syndrome/
  50. https://rarediseases.org/rare-diseases/47-xxy-klinefelter-syndrome/
  51. https://www.acmg.net/ACMG/Medical-Genetics-Practice-Resources/Practice-Guidelines.aspx
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC5788516/
  53. https://journals.biologists.com/dev/article/130/21/5065/52140/Genetic-mosaic-techniques-for-studying
  54. https://www.ncbi.nlm.nih.gov/books/NBK19725/
  55. https://journals.biologists.com/dev/article/130/20/4761/52216/Investigating-C-elegans-development-through-mosaic
  56. https://www.pnas.org/doi/10.1073/pnas.2122529119
  57. https://www.pnas.org/doi/10.1073/pnas.2021382117
  58. https://www.sciencedirect.com/science/article/pii/S0012160618302513
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC4166609/
  60. https://pubmed.ncbi.nlm.nih.gov/26984059/
  61. https://www.jbc.org/article/S0021-9258%2823%2902293-7/fulltext
  62. https://www.sciencedirect.com/science/article/pii/S0021925823022937
  63. https://www.pnas.org/doi/10.1073/pnas.2122148119
  64. https://www.sciencedirect.com/science/article/pii/S1525157823000806
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC10360090/
  66. https://onlinelibrary.wiley.com/doi/full/10.1002/mgg3.2161
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC9453383/
  68. https://www.sciencedirect.com/science/article/pii/S1028455923001353
  69. https://academic.oup.com/clinchem/article/71/10/1036/8215439
  70. https://www.nejm.org/doi/full/10.1056/NEJMoa1412690
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC9777626/
  72. https://pubmed.ncbi.nlm.nih.gov/38895972/
  73. https://www.nature.com/articles/s41467-023-36606-w
  74. https://rupress.org/jem/article/222/5/e20241045/277387/Identifying-genetic-errors-of-immunity-due-to
  75. https://www.insideprecisionmedicine.com/topics/informatics/ai-model-digs-up-rare-somatic-variants-for-precision-oncology-pipelines/
Add your contribution
Related Hubs
User Avatar
No comments yet.